Clanwilliam adds Obsidian Healthcare Group to family
21 November 2018
Global healthcare technology specialist Clanwilliam Group, which has been investing heavily in New Zealand and Australia, this week expanded into medical education with the acquisition of UK-based Obsidian Healthcare Group.
Clanwilliam Group also recently reached a €300m (just over NZ$500m) debt deal to fund its expansion plans.It completed a €200m debt placement with asset management firm Alcentra, in order to refinance existing facilities and to finance near term acquisitions, with a further €100m of follow-on capital earmarked for future growth.
Obsidian Healthcare Group is the 17th business to join Dublin-based Clanwilliam Group since it started its ambitious mergers and acquisitions (M&A) strategy in 2014.
Clanwilliam recently invested in four Australasian companies; innovative Kiwi company Konnect Net, Auckland-based Health IT company HealthLink, New Zealand pharmacy software company Toniq and New South Wales-based Medical Business Systems.
Obsidian Healthcare Group works with clinical experts to design and deliver innovative educational programmes for pharma, biotech and healthcare organisations worldwide, as well as grant providers and medical societies.
As part of Clanwilliam Group, Obsidian Healthcare Group will retain its identity and independence as it continues to support clients, grant providers and healthcare professionals.
Obsidian Healthcare Group founder and CEO Dr Wendy Mathias says becoming part of Clanwilliam Group marks a major step in expanding its ability to accomplish the educational goals of its clients and grant providers across the world.
Clanwilliam Group CEO Howard Beggs says the long-standing success Obsidian Healthcare Group has had across the world in helping to distil crucial information to healthcare professionals through high-impact education programmes, will be an invaluable asset to Clanwilliam Group.
“Not only do we expect to see new opportunities in new markets as a result of our investment in Obsidian, but the addition offers the potential to build our reputation as a trusted intermediary between innovation, clinical need and patient outcomes, as we continue to expand our M&A ambitions.”
Press released supplied by Maggie McNaughton